- Datum04.04.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1 Aktie
Verkaufen
Kaufen
GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1 Chart
GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1 Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Tradegate | VK | |||||
| Stuttgart | VK | |||||
| TTMzero Indikation | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,23 %
Intraday
-4,47 %
1 Woche
-16,20 %
1 Monat
-7,81 %
Seit Jahresbeginn
-34,33 %
1 Jahr
-47,49 %
3 Jahre
-4,85 %
5 Jahre
Wikifolio
Passender Service zu GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1
Webinar zu GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)18,480-30,500
- Jahrestief / Hoch ($)18,480-24,325
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1
Keine Dividenden verfügbar
Termine von GENMAB AS Navne Akt. (Sp. ADRs)1/10 DK 1
Keine aktuellen Termine
Beschreibung
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
